Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluphenazine Decanoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.65 |
| ▸ | FPR2 | P25090 | 12/20 | 0.68 |
| ▸ | RAD52 | P43351 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.66 |
| ▸ | USP2 | O75604 | 4/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.66 |
| ▸ | GMNN | O75496 | 2/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluphenazine Enanthate SCHEMBL3722952 | 1.00 | FPR2 (0.68) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| Fluphenazine Enanthate SCHEMBL29389566 | 0.99 | FPR2 (0.69) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| Fluphenazine Decanoate SCHEMBL41288 | 0.99 | FPR2 (0.69) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| Fluphenazine Decanoate SCHEMBL29563075 | 0.99 | FPR2 (0.69) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| Fluphenazine Enanthate SCHEMBL120793 | 0.99 | FPR2 (0.69) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5803456 | 0.99 | FPR2 (0.69) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5802453 | 0.99 | FPR2 (0.69) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5802291 | 0.99 | FPR2 (0.69) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5800312 | 0.99 | FPR2 (0.69) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5801488 | 0.99 | FPR2 (0.69) | FPR2RAD52LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | disclosed |